Tatva Chintan Pharma Chem Limited Announces Q1 FY2027 Results and Capacity Expansion Plans
Tatva Chintan Pharma Chem Limited has announced its financial results for the quarter ended June 30, 2026, alongside significant corporate developments including leadership re-appointments, a manufacturing capacity expansion, and an increase in borrowing limits.Financial Performance for Quarter Ended June 30, 2026
The company reported a steady performance for the first quarter of the fiscal year. The consolidated net profit for the period stood at Rs 159.81 million, compared to Rs 103.21 million in the preceding quarter. The total comprehensive income for the period was reported at Rs 156.62 million.On a standalone basis, the company recorded a net profit of Rs 104.46 million for the quarter ended June 30, 2026. Revenue from operations on a standalone basis was reported at Rs 1,467.02 million.
Consolidated Financial Highlights (in millions)
| Particulars | Quarter ended 30.06.2026 | Quarter ended 31.03.2026 | Quarter ended 30.06.2025 | Year ended (Audited) |
|---|---|---|---|---|
| Revenue from operations | 1,670.55 | 1,341.44 | 1,168.64 | 5,058.58 |
| Total income | 1,698.35 | 1,337.96 | 1,180.19 | 5,094.07 |
| Total expenses | 1,474.06 | 1,172.09 | 1,089.18 | 4,523.98 |
| Profit before tax | 211.11 | 165.87 | 91.01 | 570.09 |
| Net Profit for the period | 159.81 | 103.21 | 66.51 | 420.54 |
| Earnings per share (Basic) | 6.83 | 4.41 | 2.84 | 17.98 |
Standalone Financial Highlights (in millions)
| Particulars | Quarter ended 30.06.2026 | Quarter ended 31.03.2026 | Quarter ended 30.06.2025 | Year ended (Audited) |
|---|---|---|---|---|
| Revenue from operations | 1,467.02 | 1,326.65 | 1,091.80 | 4,962.96 |
| Total income | 1,507.35 | 1,322.96 | 1,105.49 | 4,998.24 |
| Total expenses | 1,353.23 | 1,173.21 | 1,034.95 | 4,466.59 |
| Profit before tax | 140.94 | 149.75 | 70.54 | 531.65 |
| Net Profit for the period | 104.46 | 90.23 | 51.33 | 390.82 |
Capacity Expansion and Strategic Growth
The Board has approved a significant expansion of manufacturing capacities for various specialty chemicals. The company will establish a new greenfield unit at Dahej - III, Dahej Industrial Estate, Taluka: Vagra, District: Bharuch, Gujarat, India.The project involves the installation of an aggregate reactor capacity of 344 kilolitres (KL). The expansion is expected to be completed within approximately 21 months, with a required investment of approximately Rs 200 Crores. The company intends to fund this expansion through a combination of internal accruals and debt.
Leadership Re-appointments
The Board, following recommendations from the Nomination and Remuneration Committee, has approved the re-appointment of key leadership members for a further period of three years from February 1, 2027, to January 31, 2030 (both days inclusive). These appointments are subject to shareholder approval at the upcoming Annual General Meeting.| Name | Designation | Tenure |
|---|---|---|
| Mr. Chintan Nitinkumar Shah | Managing Director | Feb 2027 to Jan 2030 |
| Mr. Ajaykumar Mansukhlal Patel | Whole-time Director | Feb 2027 to Jan 2030 |
| Mr. Shekhar Rasiklal Somani | Whole-time Director | Feb 2027 to Jan 2030 |
Increased Borrowing Limits
To support its growth initiatives, the Board has approved a proposal to increase the borrowing limits of the company from Rs 300,00,00,000 (Rupees Three Crores only) to Rs 1,000,00,00,000 (Rupees One Thousand Crores only). This proposal is also subject to shareholder approval at the ensuing Annual General Meeting.TATVA Stock Price Movement
Tatva Chintan Pharma Chem Limited shares edged higher to close at ₹1428.1 today, gaining 0.83% after the session. The stock saw a turnover of 126,914 shares as it stabilized above its opening price.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.